Metformin reduces the risk of poor treatment outcomes among individuals with rifampicin-resistant tuberculosis and type-2 diabetes mellitus
Year: 2024
Type: preprint
Study design: Observational Study
Abstract: We conducted a retrospective cohort study among individuals with rifampicin-resistant tuberculosis and diabetes to determine the association between metformin use and tuberculosis treatment outcomes. We found that individuals with metformin use had a significantly lower risk of poor tuberculosis treatment outcomes (adjusted RR=0.25, 95%CI 0.06 - 0.95) compared to those without.
Source: medRxiv
Institutions: Georgia State University, Stanford Medicine, Stanford University, National Center for Tuberculosis and Lung Disease, University of Georgia, David Tvildiani Medical University, Swiss Tropical and Public Health Institute, European University, Emory University, University of Massachusetts Chan Medical School
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Vanderbilt-Emory-Cornell-Duke Consortium for Global Health Fellows (VECDor), Latent tuberculosis infection and risk of type 2 diabetes mellitus in US veterans, Pulmonary impairment after tuberculosis in Georgia: Enhancing clinical research capacity to address the intersection of non-communicablediseases and tuberculosis, An Exploratory Study of Anti-Tuberculosis Drug Penetration into Cerebrospinal Fluid, Emory/Georgia TB Research Advancement Center (TRAC), Emory-Georgia TB Research Training Program
OpenAlex ID: W4400663859